Allarity Therapeutics and Detsamma Investments, trading as FivepHusion, have recently announced a significant clinical collaboration agreement for the development of Deflexifol.
Advancing Treatment for Solid Tumors
The collaboration aims to propel the clinical development of Deflexifol, a novel anti-cancer drug reformulation, for the treatment of solid tumors. Allarity will leverage its drug-specific DRP companion diagnostics to identify potential patients for enrollment in clinical trials of Deflexifol as a monotherapy and in combination with other drugs.
Addressing Limitations of Standard-of-care Chemotherapy
Deflexifol has been specifically designed to overcome the safety and efficacy limitations observed in standard-of-care 5FU chemotherapy. By reformulating this existing treatment, FivepHusion seeks to enhance patient outcomes and improve overall cancer care.
Exploring Promising Combinations and Treatment Approaches
In the second half of 2023, FivepHusion plans to initiate a phase 1b/2a study examining the combination of Deflexifol with oxaliplatin and bevacizumab as a first-line treatment for unresectable metastatic colorectal cancer patients. With an anticipated enrollment of 50 patients, this trial aims to assess the safety, tolerability, and pharmacokinetics of Deflexifol. Additionally, secondary endpoints include evaluating objective response rates and overall survival.
A Win-Win Collaboration
While the specific financial details of the collaboration, option, and potential license remain undisclosed, Allarity stands to receive milestone payments triggered by regulatory approvals of Deflexifol and the achievement of drug sales benchmarks if FivepHusion exercises its option right and obtains a license to Allarity’s DRP companion diagnostic technology.
In response to this exciting collaboration, Allarity shares experienced a surge of 30% to $3.43 in premarket trading.